Printer Friendly Version 

Investor Relations Home

Webcast ImageWebcast
1Q15 Isis Pharmaceuticals Earnings Webcast (Live)
05/05/15 at 11:30 a.m. ET
1Q15 Isis Pharmaceuticals Earnings Webcast
Tuesday, May 5, 2015 11:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
40th Annual Deutsche Bank Health Care Conference  (Live)
05/07/15 at 12:50 p.m. ET
40th Annual Deutsche Bank Health Care Conference
Thursday, May 7, 2015 12:50 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
2015 Bank of America Merrill Lynch Health Care Conference  (Live)
05/12/15 at 12:00 p.m. ET
2015 Bank of America Merrill Lynch Health Care Conference
Tuesday, May 12, 2015  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
2015 UBS Global Healthcare Conference  (Live)
05/19/15 at 12:00 p.m. ET
2015 UBS Global Healthcare Conference
Tuesday, May 19, 2015  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
ISIS (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$59.66
Change (%) Stock is Up 1.42 (2.44%)
Volume5,385,800
Data as of 05/04/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Featured Report
2013 Interactive Annual Report

Recent Press ReleasesMore >>
DateTitle 
05/04/15Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis
--Bayer to develop ISIS-FXI Rx broadly for the prevention of thrombosis-- --Transaction maximizes value of the ISIS-FXI Rx program-- --Partnership provides Isis with significant potential to participate in commercial success of ISIS-FXI Rx-- CARLSBAD, Calif., May 4, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) has entered into an exclusive license agreement with Bayer HealthCare (Bayer) to develop and commercialize ISIS-FXIRx for the prevention of thrombo... 
Printer Friendly Version
04/30/15Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen
CARLSBAD, Calif., April 30, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has earned a $10 million milestone payment from Biogen associated with the validation of an undisclosed target to treat a neurological disorder.  This is the ninth program to advance, which includes four drugs in development, under Isis' and Biogen's broad strategic alliance to discover and develop novel therapies to treat neurological and neuromuscular disorders.  "Together with B... 
Printer Friendly Version
04/29/15Webcast Alert: Isis Pharmaceuticals' First Quarter 2015 Financial Results Conference Call
CARLSBAD, Calif., April 29, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast: What: Isis Pharmaceuticals' First Quarter 2015 Financial Results When: Tuesday, May 5 at 11:30 a.m. ET / 8:30 a.m. PT Where: www.isispharm.com How: Live on the Internet. Simply log onto our website listed above. ... 
Printer Friendly Version
04/22/15Isis Pharmaceuticals Reports Positive Data From ISIS-TTR Rx in Patients With TTR Amyloidosis
Up to 92 percent reduction in transthyretin protein in patients with familial amyloid polyneuropathy CARLSBAD, Calif., April 22, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today positive data from an ongoing open-label extension (OLE) study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).  FAP patients completing the ongoing Phase 3 study are eligible to enroll in this OLE study in which all patients receive ISIS-TTRRx.  An analysis conducted... 
Printer Friendly Version
Upcoming EventsMore >>
DateTitle
05/03/15
through
05/06/15
TIDES 2015
LocationSan Diego, CA
05/03/15
through
05/07/15
ARVO 2015
LocationDenver, CO
05/05/15 11:30 a.m. ET
1Q15 Isis Pharmaceuticals Earnings Webcast
05/07/15 12:50 p.m. ET
40th Annual Deutsche Bank Health Care Conference
LocationBoston, MA
05/12/15
2015 Bank of America Merrill Lynch Health Care Conference
LocationLas Vegas, NV
05/19/15
2015 UBS Global Healthcare Conference
LocationNew York, NY
Primary IR Contact
D. Wade Walke, Ph.D.
Vice President, Corporate Communications and Investor Relations
Isis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010
Phone: 760-603-2331

For more information requests, please visit our Information Request page.

If you are interested in Isis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Online Investor Kit

Quickly download files right from our Investor Relations Web site.

Learn More

Financial Tearsheet

Download a brief overview of Isis.

Learn More

News Feeds

Get the latest.

Subscribe

Receive Isis alerts in your email.

Sign Up